Paclitaxel based devices, the current drug used for treating PAD, has raised safety concerns, and Sirolimus based devices have replaced it as a safer, more effective treatment. However, to improve bioavailability, Sirolimus based devices need to be encapsulated and retained in the artery. This has proved to be problematic.
Functionalized nanoparticles (f-NP) are employed to enable and improve uptake and retention of Sirolimus based devices in PAD patients. This allows approximately 12 million people with Peripheral Artery Disease an opportunity for better outcomes.
Dr. Mehdi Shishehbor, DO, MPH, PhD Co-Founder and CMO of Advanced NanoTherapies
Advanced NanoTherapies is working closely with the FDA to achieve an early feasibility study and introduce its technology to human populations.
Efficient balloon-to-tissue drug uptake
Sustained controlled release
Drug interchangeability and multi-drug delivery
No particle release during handling